Ambrose Healthcare is proud to announce that it has been named a finalist in the prestigious OBN Awards 2024, under the category of Best Start-Up Biotech Company.
The OBN Awards, now in their 16th year, celebrate exceptional innovation, leadership, and contributions in the life sciences industry. OBN is the UK’s most innovative life sciences membership network focused on catalyzing growth and success.
The nomination highlights Ambrose Healthcare’s commitment to addressing unmet clinical needs through our approach to developing treatments for rare diseases. Being recognized alongside other innovative companies such as CamGene Therapeutics and Tessellate BIO is a testament to the exceptional commitment of our team.
The Best Start-Up Biotech Company category shines a spotlight on early-stage UK companies that are making significant strides in the industry. Ambrose Healthcare’s inclusion as a finalist underscores the impact and vision of our team.
“We are honored to be recognized as a finalist in such a competitive and respected award,” said Toby Wilson Waterworth, Co-founder and CEO of Ambrose Healthcare. “This nomination reflects our dedication and persistence as we continue to make meaningful contributions in rare disease.”
The winners of the OBN Awards 2024 will be announced at the awards ceremony, which will take place on 20 November in London.
Ambrose Healthcare eagerly anticipates the event and is grateful for the opportunity to be acknowledged again among the best in the industry, following last year’s National Life Sciences Start-Up 2023 win.
About Ambrose Healthcare Limited
Ambrose Healthcare is an award-winning pharmaceutical start-up addressing the global need for rare disease treatments.
With only 5-10% of rare diseases having an FDA-approved treatment, Ambrose is on a mission to get safe and effective therapies onto the market and into the hands of patients quickly and cost-effectively.
For more information, please contact:
Juliet Burns, Corporate Communications